Eli Lilly $LLY stock rose 4.4% in premarket trading on Monday after full Phase 3 trial results for its experimental weight loss drug retatrutide showed participants on the highest dose losing an average of 28.3% of their body weight over 80 weeks
GIP adds metabolic improvements through pancreatic and fat tissue effects
Companies in this space include mitochondrial uncouplers with enhanced safety profiles (Rivus, Continuum), GDF15 targeting drugs (Novo, Lilly, Janssen), anti- activin II receptor mAb (Versanis), mir-22 inhibition (Resalis Tx) and gut-brain axis modulators (Kallyope)
Week 7-12: adaptation phase For most people, gastrointestinal side effects diminish substantially by weeks seven to twelve, even as they continue titrating to higher doses
The only trial-backed oral semaglutide is brand Wegovys FDA-approved pill at $149 a month through NovoCare
The ideal future medication might produce permanent weight loss even after discontinuation
